Global Bispecific Antibodies Market

Bispecific Antibodies Comprehensive Study by Type (Trifunctional Antibodies, Chemically Linked Fabs, Bispecific T Cell Engagers (BiTEs).), Application (Hospitals, Diagnostic Centers, Academic and Research Institutes), Drug (Blinatumab, Catumaxomab, Duligotumab), Indication (Cancer, Infectious Disease, Inflammatory and Autoimmune Disorders, CNS Disorders), Distribution Channel (Hospital pharmacies, Retail pharmacies, Online pharmacies) Players and Region - Global Market Outlook to 2027

Bispecific Antibodies Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Bispecific Antibodies
Bispecific antibody (BsAb) is an artificial protein made up of fragments from two monoclonal antibodies that can bind to two different types of antigens. The most well-studied application of bispecific antibodies is cancer immunotherapy. BsAb has a broader range of uses, including lung, breast, and colon cancer. The major players in the global bispecific antibodies market are concentrating their efforts on developing and launching new products. These medications are still under development and are expected to have a promising future. Manufacturers are always attempting to improve these items in response to the increased occurrence of cancer, which necessitates better therapeutic treatment.

AttributesDetails
Study Period2017-2027
Base Year2021
UnitValue (USD Million)


The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Bispecific Antibodies market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Amgen, Inc. (United States), Bayer AG (Germany), Dow Pharmaceutical Solutions, ImmunGene, Inc., Immunocore Limited (United Kingdom), Merck & Co., Inc. (United States), Novartis AG (Switzerland), Pfizer, Inc. (United States) and F. Hoffmann-La Roche AG (Switzerland) are some of the key players that are part of study coverage.

Segmentation Overview
AMA Research has segmented the market of Global Bispecific Antibodies market by Type (Trifunctional Antibodies, Chemically Linked Fabs and Bispecific T Cell Engagers (BiTEs).), Application (Hospitals, Diagnostic Centers and Academic and Research Institutes) and Region.



On the basis of geography, the market of Bispecific Antibodies has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Drug, the sub-segment i.e. Blinatumab will boost the Bispecific Antibodies market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Indication, the sub-segment i.e. Cancer will boost the Bispecific Antibodies market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Distribution Channel, the sub-segment i.e. Hospital pharmacies will boost the Bispecific Antibodies market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Leaders and their expansionary development strategies
In January 2021, Research & development group of Eli Lilly and Company, Loxo Oncology collaborated with Netherlands-based biotechnology company, Merus N.V. to discover Novel T-Cell re-directing bispecific antibodies. With this collaboration, Loxo Oncology will be responsible for additional research, development, and commercialization activities, while Merus will lead discovery and early-stage research activities. The transaction will also allow Loxo Oncology to leverage Merus' proprietary Biclonics platform for R&D of three CD3-engaging T-cell re-directing bispecific antibody therapies.
In December 2020, Pfizer reported positive clinical data for BCMA-CD3 bispecific antibody in multiple myeloma., and In January 2019, the Chinese Academy of Medical Sciences & Peking Union Medical College developed a new bispecific aptamer that enhances immune cytotoxicity against MUC1-positive tumor cells.
In June 2022, Roche Holding AG, a pharmaceutical company received approval from European Commission for its first CD20xCD3 T-cell engaging bispecific antibody. The approval is specifically for the treatment of adult patients with relapsed or refractory FL and who have received at least two prior systemic therapies.

Market Drivers
  • Rising Prevalence of Different Types of Cancer
  • Manufacturers in the market are Collaborating with Regional Biotech Companies for the Development of Bispecific Antibodies

Opportunities
  • Favorable Initiatives Taken by the Federal Government
  • Increasing Healthcare Access and Awareness in Developing Region

Restraints
  • Technical Complexity associated with the Treatment Procedure (detection) of Bispecific Antibodies

Challenges
  • Lack of Awareness


Key Target Audience
Venture Capitalists and Private Equity Firms, New Entrants/Investors, Analysts and Strategic Business Planners, Government Regulatory and Research Organizations, Bispecific Antibodies Provider and End-Use Industries

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have the better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with purpose to understand company’s positioning regarding market value, volume and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders etc. and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, analyst team keeps preparing set of questionnaires and after getting appointee list; the target audience are then tapped and segregated with various mediums and channels that are feasible for making connection that includes email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey etc.

Report Objectives / Segmentation Covered

By Type
  • Trifunctional Antibodies
  • Chemically Linked Fabs
  • Bispecific T Cell Engagers (BiTEs).
By Application
  • Hospitals
  • Diagnostic Centers
  • Academic and Research Institutes
By Drug
  • Blinatumab
  • Catumaxomab
  • Duligotumab

By Indication
  • Cancer
  • Infectious Disease
  • Inflammatory and Autoimmune Disorders
  • CNS Disorders

By Distribution Channel
  • Hospital pharmacies
  • Retail pharmacies
  • Online pharmacies

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Prevalence of Different Types of Cancer
      • 3.2.2. Manufacturers in the market are Collaborating with Regional Biotech Companies for the Development of Bispecific Antibodies
    • 3.3. Market Challenges
      • 3.3.1. Lack of Awareness
    • 3.4. Market Trends
      • 3.4.1. Increase in Advanced Research Activities
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Bispecific Antibodies, by Type, Application, Drug, Indication, Distribution Channel and Region (value and price ) (2016-2021)
    • 5.1. Introduction
    • 5.2. Global Bispecific Antibodies (Value)
      • 5.2.1. Global Bispecific Antibodies by: Type (Value)
        • 5.2.1.1. Trifunctional Antibodies
        • 5.2.1.2. Chemically Linked Fabs
        • 5.2.1.3. Bispecific T Cell Engagers (BiTEs).
      • 5.2.2. Global Bispecific Antibodies by: Application (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Diagnostic Centers
        • 5.2.2.3. Academic and Research Institutes
      • 5.2.3. Global Bispecific Antibodies by: Drug (Value)
        • 5.2.3.1. Blinatumab
        • 5.2.3.2. Catumaxomab
        • 5.2.3.3. Duligotumab
      • 5.2.4. Global Bispecific Antibodies by: Indication (Value)
        • 5.2.4.1. Cancer
        • 5.2.4.2. Infectious Disease
        • 5.2.4.3. Inflammatory and Autoimmune Disorders
        • 5.2.4.4. CNS Disorders
      • 5.2.5. Global Bispecific Antibodies by: Distribution Channel (Value)
        • 5.2.5.1. Hospital pharmacies
        • 5.2.5.2. Retail pharmacies
        • 5.2.5.3. Online pharmacies
      • 5.2.6. Global Bispecific Antibodies Region
        • 5.2.6.1. South America
          • 5.2.6.1.1. Brazil
          • 5.2.6.1.2. Argentina
          • 5.2.6.1.3. Rest of South America
        • 5.2.6.2. Asia Pacific
          • 5.2.6.2.1. China
          • 5.2.6.2.2. Japan
          • 5.2.6.2.3. India
          • 5.2.6.2.4. South Korea
          • 5.2.6.2.5. Taiwan
          • 5.2.6.2.6. Australia
          • 5.2.6.2.7. Rest of Asia-Pacific
        • 5.2.6.3. Europe
          • 5.2.6.3.1. Germany
          • 5.2.6.3.2. France
          • 5.2.6.3.3. Italy
          • 5.2.6.3.4. United Kingdom
          • 5.2.6.3.5. Netherlands
          • 5.2.6.3.6. Rest of Europe
        • 5.2.6.4. MEA
          • 5.2.6.4.1. Middle East
          • 5.2.6.4.2. Africa
        • 5.2.6.5. North America
          • 5.2.6.5.1. United States
          • 5.2.6.5.2. Canada
          • 5.2.6.5.3. Mexico
    • 5.3. Global Bispecific Antibodies (Price)
      • 5.3.1. Global Bispecific Antibodies by: Type (Price)
  • 6. Bispecific Antibodies: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2021)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Amgen, Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Bayer AG (Germany)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Dow Pharmaceutical Solutions
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. ImmunGene, Inc.
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Immunocore Limited (United Kingdom)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Merck & Co., Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Novartis AG (Switzerland)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Pfizer, Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. F. Hoffmann-La Roche AG (Switzerland)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
  • 7. Global Bispecific Antibodies Sale, by Type, Application, Drug, Indication, Distribution Channel and Region (value and price ) (2022-2027)
    • 7.1. Introduction
    • 7.2. Global Bispecific Antibodies (Value)
      • 7.2.1. Global Bispecific Antibodies by: Type (Value)
        • 7.2.1.1. Trifunctional Antibodies
        • 7.2.1.2. Chemically Linked Fabs
        • 7.2.1.3. Bispecific T Cell Engagers (BiTEs).
      • 7.2.2. Global Bispecific Antibodies by: Application (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Diagnostic Centers
        • 7.2.2.3. Academic and Research Institutes
      • 7.2.3. Global Bispecific Antibodies by: Drug (Value)
        • 7.2.3.1. Blinatumab
        • 7.2.3.2. Catumaxomab
        • 7.2.3.3. Duligotumab
      • 7.2.4. Global Bispecific Antibodies by: Indication (Value)
        • 7.2.4.1. Cancer
        • 7.2.4.2. Infectious Disease
        • 7.2.4.3. Inflammatory and Autoimmune Disorders
        • 7.2.4.4. CNS Disorders
      • 7.2.5. Global Bispecific Antibodies by: Distribution Channel (Value)
        • 7.2.5.1. Hospital pharmacies
        • 7.2.5.2. Retail pharmacies
        • 7.2.5.3. Online pharmacies
      • 7.2.6. Global Bispecific Antibodies Region
        • 7.2.6.1. South America
          • 7.2.6.1.1. Brazil
          • 7.2.6.1.2. Argentina
          • 7.2.6.1.3. Rest of South America
        • 7.2.6.2. Asia Pacific
          • 7.2.6.2.1. China
          • 7.2.6.2.2. Japan
          • 7.2.6.2.3. India
          • 7.2.6.2.4. South Korea
          • 7.2.6.2.5. Taiwan
          • 7.2.6.2.6. Australia
          • 7.2.6.2.7. Rest of Asia-Pacific
        • 7.2.6.3. Europe
          • 7.2.6.3.1. Germany
          • 7.2.6.3.2. France
          • 7.2.6.3.3. Italy
          • 7.2.6.3.4. United Kingdom
          • 7.2.6.3.5. Netherlands
          • 7.2.6.3.6. Rest of Europe
        • 7.2.6.4. MEA
          • 7.2.6.4.1. Middle East
          • 7.2.6.4.2. Africa
        • 7.2.6.5. North America
          • 7.2.6.5.1. United States
          • 7.2.6.5.2. Canada
          • 7.2.6.5.3. Mexico
    • 7.3. Global Bispecific Antibodies (Price)
      • 7.3.1. Global Bispecific Antibodies by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Bispecific Antibodies: by Type(USD Million)
  • Table 2. Bispecific Antibodies Trifunctional Antibodies , by Region USD Million (2016-2021)
  • Table 3. Bispecific Antibodies Chemically Linked Fabs , by Region USD Million (2016-2021)
  • Table 4. Bispecific Antibodies Bispecific T Cell Engagers (BiTEs). , by Region USD Million (2016-2021)
  • Table 5. Bispecific Antibodies: by Application(USD Million)
  • Table 6. Bispecific Antibodies Hospitals , by Region USD Million (2016-2021)
  • Table 7. Bispecific Antibodies Diagnostic Centers , by Region USD Million (2016-2021)
  • Table 8. Bispecific Antibodies Academic and Research Institutes , by Region USD Million (2016-2021)
  • Table 9. Bispecific Antibodies: by Drug(USD Million)
  • Table 10. Bispecific Antibodies Blinatumab , by Region USD Million (2016-2021)
  • Table 11. Bispecific Antibodies Catumaxomab , by Region USD Million (2016-2021)
  • Table 12. Bispecific Antibodies Duligotumab , by Region USD Million (2016-2021)
  • Table 13. Bispecific Antibodies: by Indication(USD Million)
  • Table 14. Bispecific Antibodies Cancer , by Region USD Million (2016-2021)
  • Table 15. Bispecific Antibodies Infectious Disease , by Region USD Million (2016-2021)
  • Table 16. Bispecific Antibodies Inflammatory and Autoimmune Disorders , by Region USD Million (2016-2021)
  • Table 17. Bispecific Antibodies CNS Disorders , by Region USD Million (2016-2021)
  • Table 18. Bispecific Antibodies: by Distribution Channel(USD Million)
  • Table 19. Bispecific Antibodies Hospital pharmacies , by Region USD Million (2016-2021)
  • Table 20. Bispecific Antibodies Retail pharmacies , by Region USD Million (2016-2021)
  • Table 21. Bispecific Antibodies Online pharmacies , by Region USD Million (2016-2021)
  • Table 22. South America Bispecific Antibodies, by Country USD Million (2016-2021)
  • Table 23. South America Bispecific Antibodies, by Type USD Million (2016-2021)
  • Table 24. South America Bispecific Antibodies, by Application USD Million (2016-2021)
  • Table 25. South America Bispecific Antibodies, by Drug USD Million (2016-2021)
  • Table 26. South America Bispecific Antibodies, by Indication USD Million (2016-2021)
  • Table 27. South America Bispecific Antibodies, by Distribution Channel USD Million (2016-2021)
  • Table 28. Brazil Bispecific Antibodies, by Type USD Million (2016-2021)
  • Table 29. Brazil Bispecific Antibodies, by Application USD Million (2016-2021)
  • Table 30. Brazil Bispecific Antibodies, by Drug USD Million (2016-2021)
  • Table 31. Brazil Bispecific Antibodies, by Indication USD Million (2016-2021)
  • Table 32. Brazil Bispecific Antibodies, by Distribution Channel USD Million (2016-2021)
  • Table 33. Argentina Bispecific Antibodies, by Type USD Million (2016-2021)
  • Table 34. Argentina Bispecific Antibodies, by Application USD Million (2016-2021)
  • Table 35. Argentina Bispecific Antibodies, by Drug USD Million (2016-2021)
  • Table 36. Argentina Bispecific Antibodies, by Indication USD Million (2016-2021)
  • Table 37. Argentina Bispecific Antibodies, by Distribution Channel USD Million (2016-2021)
  • Table 38. Rest of South America Bispecific Antibodies, by Type USD Million (2016-2021)
  • Table 39. Rest of South America Bispecific Antibodies, by Application USD Million (2016-2021)
  • Table 40. Rest of South America Bispecific Antibodies, by Drug USD Million (2016-2021)
  • Table 41. Rest of South America Bispecific Antibodies, by Indication USD Million (2016-2021)
  • Table 42. Rest of South America Bispecific Antibodies, by Distribution Channel USD Million (2016-2021)
  • Table 43. Asia Pacific Bispecific Antibodies, by Country USD Million (2016-2021)
  • Table 44. Asia Pacific Bispecific Antibodies, by Type USD Million (2016-2021)
  • Table 45. Asia Pacific Bispecific Antibodies, by Application USD Million (2016-2021)
  • Table 46. Asia Pacific Bispecific Antibodies, by Drug USD Million (2016-2021)
  • Table 47. Asia Pacific Bispecific Antibodies, by Indication USD Million (2016-2021)
  • Table 48. Asia Pacific Bispecific Antibodies, by Distribution Channel USD Million (2016-2021)
  • Table 49. China Bispecific Antibodies, by Type USD Million (2016-2021)
  • Table 50. China Bispecific Antibodies, by Application USD Million (2016-2021)
  • Table 51. China Bispecific Antibodies, by Drug USD Million (2016-2021)
  • Table 52. China Bispecific Antibodies, by Indication USD Million (2016-2021)
  • Table 53. China Bispecific Antibodies, by Distribution Channel USD Million (2016-2021)
  • Table 54. Japan Bispecific Antibodies, by Type USD Million (2016-2021)
  • Table 55. Japan Bispecific Antibodies, by Application USD Million (2016-2021)
  • Table 56. Japan Bispecific Antibodies, by Drug USD Million (2016-2021)
  • Table 57. Japan Bispecific Antibodies, by Indication USD Million (2016-2021)
  • Table 58. Japan Bispecific Antibodies, by Distribution Channel USD Million (2016-2021)
  • Table 59. India Bispecific Antibodies, by Type USD Million (2016-2021)
  • Table 60. India Bispecific Antibodies, by Application USD Million (2016-2021)
  • Table 61. India Bispecific Antibodies, by Drug USD Million (2016-2021)
  • Table 62. India Bispecific Antibodies, by Indication USD Million (2016-2021)
  • Table 63. India Bispecific Antibodies, by Distribution Channel USD Million (2016-2021)
  • Table 64. South Korea Bispecific Antibodies, by Type USD Million (2016-2021)
  • Table 65. South Korea Bispecific Antibodies, by Application USD Million (2016-2021)
  • Table 66. South Korea Bispecific Antibodies, by Drug USD Million (2016-2021)
  • Table 67. South Korea Bispecific Antibodies, by Indication USD Million (2016-2021)
  • Table 68. South Korea Bispecific Antibodies, by Distribution Channel USD Million (2016-2021)
  • Table 69. Taiwan Bispecific Antibodies, by Type USD Million (2016-2021)
  • Table 70. Taiwan Bispecific Antibodies, by Application USD Million (2016-2021)
  • Table 71. Taiwan Bispecific Antibodies, by Drug USD Million (2016-2021)
  • Table 72. Taiwan Bispecific Antibodies, by Indication USD Million (2016-2021)
  • Table 73. Taiwan Bispecific Antibodies, by Distribution Channel USD Million (2016-2021)
  • Table 74. Australia Bispecific Antibodies, by Type USD Million (2016-2021)
  • Table 75. Australia Bispecific Antibodies, by Application USD Million (2016-2021)
  • Table 76. Australia Bispecific Antibodies, by Drug USD Million (2016-2021)
  • Table 77. Australia Bispecific Antibodies, by Indication USD Million (2016-2021)
  • Table 78. Australia Bispecific Antibodies, by Distribution Channel USD Million (2016-2021)
  • Table 79. Rest of Asia-Pacific Bispecific Antibodies, by Type USD Million (2016-2021)
  • Table 80. Rest of Asia-Pacific Bispecific Antibodies, by Application USD Million (2016-2021)
  • Table 81. Rest of Asia-Pacific Bispecific Antibodies, by Drug USD Million (2016-2021)
  • Table 82. Rest of Asia-Pacific Bispecific Antibodies, by Indication USD Million (2016-2021)
  • Table 83. Rest of Asia-Pacific Bispecific Antibodies, by Distribution Channel USD Million (2016-2021)
  • Table 84. Europe Bispecific Antibodies, by Country USD Million (2016-2021)
  • Table 85. Europe Bispecific Antibodies, by Type USD Million (2016-2021)
  • Table 86. Europe Bispecific Antibodies, by Application USD Million (2016-2021)
  • Table 87. Europe Bispecific Antibodies, by Drug USD Million (2016-2021)
  • Table 88. Europe Bispecific Antibodies, by Indication USD Million (2016-2021)
  • Table 89. Europe Bispecific Antibodies, by Distribution Channel USD Million (2016-2021)
  • Table 90. Germany Bispecific Antibodies, by Type USD Million (2016-2021)
  • Table 91. Germany Bispecific Antibodies, by Application USD Million (2016-2021)
  • Table 92. Germany Bispecific Antibodies, by Drug USD Million (2016-2021)
  • Table 93. Germany Bispecific Antibodies, by Indication USD Million (2016-2021)
  • Table 94. Germany Bispecific Antibodies, by Distribution Channel USD Million (2016-2021)
  • Table 95. France Bispecific Antibodies, by Type USD Million (2016-2021)
  • Table 96. France Bispecific Antibodies, by Application USD Million (2016-2021)
  • Table 97. France Bispecific Antibodies, by Drug USD Million (2016-2021)
  • Table 98. France Bispecific Antibodies, by Indication USD Million (2016-2021)
  • Table 99. France Bispecific Antibodies, by Distribution Channel USD Million (2016-2021)
  • Table 100. Italy Bispecific Antibodies, by Type USD Million (2016-2021)
  • Table 101. Italy Bispecific Antibodies, by Application USD Million (2016-2021)
  • Table 102. Italy Bispecific Antibodies, by Drug USD Million (2016-2021)
  • Table 103. Italy Bispecific Antibodies, by Indication USD Million (2016-2021)
  • Table 104. Italy Bispecific Antibodies, by Distribution Channel USD Million (2016-2021)
  • Table 105. United Kingdom Bispecific Antibodies, by Type USD Million (2016-2021)
  • Table 106. United Kingdom Bispecific Antibodies, by Application USD Million (2016-2021)
  • Table 107. United Kingdom Bispecific Antibodies, by Drug USD Million (2016-2021)
  • Table 108. United Kingdom Bispecific Antibodies, by Indication USD Million (2016-2021)
  • Table 109. United Kingdom Bispecific Antibodies, by Distribution Channel USD Million (2016-2021)
  • Table 110. Netherlands Bispecific Antibodies, by Type USD Million (2016-2021)
  • Table 111. Netherlands Bispecific Antibodies, by Application USD Million (2016-2021)
  • Table 112. Netherlands Bispecific Antibodies, by Drug USD Million (2016-2021)
  • Table 113. Netherlands Bispecific Antibodies, by Indication USD Million (2016-2021)
  • Table 114. Netherlands Bispecific Antibodies, by Distribution Channel USD Million (2016-2021)
  • Table 115. Rest of Europe Bispecific Antibodies, by Type USD Million (2016-2021)
  • Table 116. Rest of Europe Bispecific Antibodies, by Application USD Million (2016-2021)
  • Table 117. Rest of Europe Bispecific Antibodies, by Drug USD Million (2016-2021)
  • Table 118. Rest of Europe Bispecific Antibodies, by Indication USD Million (2016-2021)
  • Table 119. Rest of Europe Bispecific Antibodies, by Distribution Channel USD Million (2016-2021)
  • Table 120. MEA Bispecific Antibodies, by Country USD Million (2016-2021)
  • Table 121. MEA Bispecific Antibodies, by Type USD Million (2016-2021)
  • Table 122. MEA Bispecific Antibodies, by Application USD Million (2016-2021)
  • Table 123. MEA Bispecific Antibodies, by Drug USD Million (2016-2021)
  • Table 124. MEA Bispecific Antibodies, by Indication USD Million (2016-2021)
  • Table 125. MEA Bispecific Antibodies, by Distribution Channel USD Million (2016-2021)
  • Table 126. Middle East Bispecific Antibodies, by Type USD Million (2016-2021)
  • Table 127. Middle East Bispecific Antibodies, by Application USD Million (2016-2021)
  • Table 128. Middle East Bispecific Antibodies, by Drug USD Million (2016-2021)
  • Table 129. Middle East Bispecific Antibodies, by Indication USD Million (2016-2021)
  • Table 130. Middle East Bispecific Antibodies, by Distribution Channel USD Million (2016-2021)
  • Table 131. Africa Bispecific Antibodies, by Type USD Million (2016-2021)
  • Table 132. Africa Bispecific Antibodies, by Application USD Million (2016-2021)
  • Table 133. Africa Bispecific Antibodies, by Drug USD Million (2016-2021)
  • Table 134. Africa Bispecific Antibodies, by Indication USD Million (2016-2021)
  • Table 135. Africa Bispecific Antibodies, by Distribution Channel USD Million (2016-2021)
  • Table 136. North America Bispecific Antibodies, by Country USD Million (2016-2021)
  • Table 137. North America Bispecific Antibodies, by Type USD Million (2016-2021)
  • Table 138. North America Bispecific Antibodies, by Application USD Million (2016-2021)
  • Table 139. North America Bispecific Antibodies, by Drug USD Million (2016-2021)
  • Table 140. North America Bispecific Antibodies, by Indication USD Million (2016-2021)
  • Table 141. North America Bispecific Antibodies, by Distribution Channel USD Million (2016-2021)
  • Table 142. United States Bispecific Antibodies, by Type USD Million (2016-2021)
  • Table 143. United States Bispecific Antibodies, by Application USD Million (2016-2021)
  • Table 144. United States Bispecific Antibodies, by Drug USD Million (2016-2021)
  • Table 145. United States Bispecific Antibodies, by Indication USD Million (2016-2021)
  • Table 146. United States Bispecific Antibodies, by Distribution Channel USD Million (2016-2021)
  • Table 147. Canada Bispecific Antibodies, by Type USD Million (2016-2021)
  • Table 148. Canada Bispecific Antibodies, by Application USD Million (2016-2021)
  • Table 149. Canada Bispecific Antibodies, by Drug USD Million (2016-2021)
  • Table 150. Canada Bispecific Antibodies, by Indication USD Million (2016-2021)
  • Table 151. Canada Bispecific Antibodies, by Distribution Channel USD Million (2016-2021)
  • Table 152. Mexico Bispecific Antibodies, by Type USD Million (2016-2021)
  • Table 153. Mexico Bispecific Antibodies, by Application USD Million (2016-2021)
  • Table 154. Mexico Bispecific Antibodies, by Drug USD Million (2016-2021)
  • Table 155. Mexico Bispecific Antibodies, by Indication USD Million (2016-2021)
  • Table 156. Mexico Bispecific Antibodies, by Distribution Channel USD Million (2016-2021)
  • Table 157. Bispecific Antibodies: by Type(USD/Units)
  • Table 158. Company Basic Information, Sales Area and Its Competitors
  • Table 159. Company Basic Information, Sales Area and Its Competitors
  • Table 160. Company Basic Information, Sales Area and Its Competitors
  • Table 161. Company Basic Information, Sales Area and Its Competitors
  • Table 162. Company Basic Information, Sales Area and Its Competitors
  • Table 163. Company Basic Information, Sales Area and Its Competitors
  • Table 164. Company Basic Information, Sales Area and Its Competitors
  • Table 165. Company Basic Information, Sales Area and Its Competitors
  • Table 166. Company Basic Information, Sales Area and Its Competitors
  • Table 167. Bispecific Antibodies: by Type(USD Million)
  • Table 168. Bispecific Antibodies Trifunctional Antibodies , by Region USD Million (2022-2027)
  • Table 169. Bispecific Antibodies Chemically Linked Fabs , by Region USD Million (2022-2027)
  • Table 170. Bispecific Antibodies Bispecific T Cell Engagers (BiTEs). , by Region USD Million (2022-2027)
  • Table 171. Bispecific Antibodies: by Application(USD Million)
  • Table 172. Bispecific Antibodies Hospitals , by Region USD Million (2022-2027)
  • Table 173. Bispecific Antibodies Diagnostic Centers , by Region USD Million (2022-2027)
  • Table 174. Bispecific Antibodies Academic and Research Institutes , by Region USD Million (2022-2027)
  • Table 175. Bispecific Antibodies: by Drug(USD Million)
  • Table 176. Bispecific Antibodies Blinatumab , by Region USD Million (2022-2027)
  • Table 177. Bispecific Antibodies Catumaxomab , by Region USD Million (2022-2027)
  • Table 178. Bispecific Antibodies Duligotumab , by Region USD Million (2022-2027)
  • Table 179. Bispecific Antibodies: by Indication(USD Million)
  • Table 180. Bispecific Antibodies Cancer , by Region USD Million (2022-2027)
  • Table 181. Bispecific Antibodies Infectious Disease , by Region USD Million (2022-2027)
  • Table 182. Bispecific Antibodies Inflammatory and Autoimmune Disorders , by Region USD Million (2022-2027)
  • Table 183. Bispecific Antibodies CNS Disorders , by Region USD Million (2022-2027)
  • Table 184. Bispecific Antibodies: by Distribution Channel(USD Million)
  • Table 185. Bispecific Antibodies Hospital pharmacies , by Region USD Million (2022-2027)
  • Table 186. Bispecific Antibodies Retail pharmacies , by Region USD Million (2022-2027)
  • Table 187. Bispecific Antibodies Online pharmacies , by Region USD Million (2022-2027)
  • Table 188. South America Bispecific Antibodies, by Country USD Million (2022-2027)
  • Table 189. South America Bispecific Antibodies, by Type USD Million (2022-2027)
  • Table 190. South America Bispecific Antibodies, by Application USD Million (2022-2027)
  • Table 191. South America Bispecific Antibodies, by Drug USD Million (2022-2027)
  • Table 192. South America Bispecific Antibodies, by Indication USD Million (2022-2027)
  • Table 193. South America Bispecific Antibodies, by Distribution Channel USD Million (2022-2027)
  • Table 194. Brazil Bispecific Antibodies, by Type USD Million (2022-2027)
  • Table 195. Brazil Bispecific Antibodies, by Application USD Million (2022-2027)
  • Table 196. Brazil Bispecific Antibodies, by Drug USD Million (2022-2027)
  • Table 197. Brazil Bispecific Antibodies, by Indication USD Million (2022-2027)
  • Table 198. Brazil Bispecific Antibodies, by Distribution Channel USD Million (2022-2027)
  • Table 199. Argentina Bispecific Antibodies, by Type USD Million (2022-2027)
  • Table 200. Argentina Bispecific Antibodies, by Application USD Million (2022-2027)
  • Table 201. Argentina Bispecific Antibodies, by Drug USD Million (2022-2027)
  • Table 202. Argentina Bispecific Antibodies, by Indication USD Million (2022-2027)
  • Table 203. Argentina Bispecific Antibodies, by Distribution Channel USD Million (2022-2027)
  • Table 204. Rest of South America Bispecific Antibodies, by Type USD Million (2022-2027)
  • Table 205. Rest of South America Bispecific Antibodies, by Application USD Million (2022-2027)
  • Table 206. Rest of South America Bispecific Antibodies, by Drug USD Million (2022-2027)
  • Table 207. Rest of South America Bispecific Antibodies, by Indication USD Million (2022-2027)
  • Table 208. Rest of South America Bispecific Antibodies, by Distribution Channel USD Million (2022-2027)
  • Table 209. Asia Pacific Bispecific Antibodies, by Country USD Million (2022-2027)
  • Table 210. Asia Pacific Bispecific Antibodies, by Type USD Million (2022-2027)
  • Table 211. Asia Pacific Bispecific Antibodies, by Application USD Million (2022-2027)
  • Table 212. Asia Pacific Bispecific Antibodies, by Drug USD Million (2022-2027)
  • Table 213. Asia Pacific Bispecific Antibodies, by Indication USD Million (2022-2027)
  • Table 214. Asia Pacific Bispecific Antibodies, by Distribution Channel USD Million (2022-2027)
  • Table 215. China Bispecific Antibodies, by Type USD Million (2022-2027)
  • Table 216. China Bispecific Antibodies, by Application USD Million (2022-2027)
  • Table 217. China Bispecific Antibodies, by Drug USD Million (2022-2027)
  • Table 218. China Bispecific Antibodies, by Indication USD Million (2022-2027)
  • Table 219. China Bispecific Antibodies, by Distribution Channel USD Million (2022-2027)
  • Table 220. Japan Bispecific Antibodies, by Type USD Million (2022-2027)
  • Table 221. Japan Bispecific Antibodies, by Application USD Million (2022-2027)
  • Table 222. Japan Bispecific Antibodies, by Drug USD Million (2022-2027)
  • Table 223. Japan Bispecific Antibodies, by Indication USD Million (2022-2027)
  • Table 224. Japan Bispecific Antibodies, by Distribution Channel USD Million (2022-2027)
  • Table 225. India Bispecific Antibodies, by Type USD Million (2022-2027)
  • Table 226. India Bispecific Antibodies, by Application USD Million (2022-2027)
  • Table 227. India Bispecific Antibodies, by Drug USD Million (2022-2027)
  • Table 228. India Bispecific Antibodies, by Indication USD Million (2022-2027)
  • Table 229. India Bispecific Antibodies, by Distribution Channel USD Million (2022-2027)
  • Table 230. South Korea Bispecific Antibodies, by Type USD Million (2022-2027)
  • Table 231. South Korea Bispecific Antibodies, by Application USD Million (2022-2027)
  • Table 232. South Korea Bispecific Antibodies, by Drug USD Million (2022-2027)
  • Table 233. South Korea Bispecific Antibodies, by Indication USD Million (2022-2027)
  • Table 234. South Korea Bispecific Antibodies, by Distribution Channel USD Million (2022-2027)
  • Table 235. Taiwan Bispecific Antibodies, by Type USD Million (2022-2027)
  • Table 236. Taiwan Bispecific Antibodies, by Application USD Million (2022-2027)
  • Table 237. Taiwan Bispecific Antibodies, by Drug USD Million (2022-2027)
  • Table 238. Taiwan Bispecific Antibodies, by Indication USD Million (2022-2027)
  • Table 239. Taiwan Bispecific Antibodies, by Distribution Channel USD Million (2022-2027)
  • Table 240. Australia Bispecific Antibodies, by Type USD Million (2022-2027)
  • Table 241. Australia Bispecific Antibodies, by Application USD Million (2022-2027)
  • Table 242. Australia Bispecific Antibodies, by Drug USD Million (2022-2027)
  • Table 243. Australia Bispecific Antibodies, by Indication USD Million (2022-2027)
  • Table 244. Australia Bispecific Antibodies, by Distribution Channel USD Million (2022-2027)
  • Table 245. Rest of Asia-Pacific Bispecific Antibodies, by Type USD Million (2022-2027)
  • Table 246. Rest of Asia-Pacific Bispecific Antibodies, by Application USD Million (2022-2027)
  • Table 247. Rest of Asia-Pacific Bispecific Antibodies, by Drug USD Million (2022-2027)
  • Table 248. Rest of Asia-Pacific Bispecific Antibodies, by Indication USD Million (2022-2027)
  • Table 249. Rest of Asia-Pacific Bispecific Antibodies, by Distribution Channel USD Million (2022-2027)
  • Table 250. Europe Bispecific Antibodies, by Country USD Million (2022-2027)
  • Table 251. Europe Bispecific Antibodies, by Type USD Million (2022-2027)
  • Table 252. Europe Bispecific Antibodies, by Application USD Million (2022-2027)
  • Table 253. Europe Bispecific Antibodies, by Drug USD Million (2022-2027)
  • Table 254. Europe Bispecific Antibodies, by Indication USD Million (2022-2027)
  • Table 255. Europe Bispecific Antibodies, by Distribution Channel USD Million (2022-2027)
  • Table 256. Germany Bispecific Antibodies, by Type USD Million (2022-2027)
  • Table 257. Germany Bispecific Antibodies, by Application USD Million (2022-2027)
  • Table 258. Germany Bispecific Antibodies, by Drug USD Million (2022-2027)
  • Table 259. Germany Bispecific Antibodies, by Indication USD Million (2022-2027)
  • Table 260. Germany Bispecific Antibodies, by Distribution Channel USD Million (2022-2027)
  • Table 261. France Bispecific Antibodies, by Type USD Million (2022-2027)
  • Table 262. France Bispecific Antibodies, by Application USD Million (2022-2027)
  • Table 263. France Bispecific Antibodies, by Drug USD Million (2022-2027)
  • Table 264. France Bispecific Antibodies, by Indication USD Million (2022-2027)
  • Table 265. France Bispecific Antibodies, by Distribution Channel USD Million (2022-2027)
  • Table 266. Italy Bispecific Antibodies, by Type USD Million (2022-2027)
  • Table 267. Italy Bispecific Antibodies, by Application USD Million (2022-2027)
  • Table 268. Italy Bispecific Antibodies, by Drug USD Million (2022-2027)
  • Table 269. Italy Bispecific Antibodies, by Indication USD Million (2022-2027)
  • Table 270. Italy Bispecific Antibodies, by Distribution Channel USD Million (2022-2027)
  • Table 271. United Kingdom Bispecific Antibodies, by Type USD Million (2022-2027)
  • Table 272. United Kingdom Bispecific Antibodies, by Application USD Million (2022-2027)
  • Table 273. United Kingdom Bispecific Antibodies, by Drug USD Million (2022-2027)
  • Table 274. United Kingdom Bispecific Antibodies, by Indication USD Million (2022-2027)
  • Table 275. United Kingdom Bispecific Antibodies, by Distribution Channel USD Million (2022-2027)
  • Table 276. Netherlands Bispecific Antibodies, by Type USD Million (2022-2027)
  • Table 277. Netherlands Bispecific Antibodies, by Application USD Million (2022-2027)
  • Table 278. Netherlands Bispecific Antibodies, by Drug USD Million (2022-2027)
  • Table 279. Netherlands Bispecific Antibodies, by Indication USD Million (2022-2027)
  • Table 280. Netherlands Bispecific Antibodies, by Distribution Channel USD Million (2022-2027)
  • Table 281. Rest of Europe Bispecific Antibodies, by Type USD Million (2022-2027)
  • Table 282. Rest of Europe Bispecific Antibodies, by Application USD Million (2022-2027)
  • Table 283. Rest of Europe Bispecific Antibodies, by Drug USD Million (2022-2027)
  • Table 284. Rest of Europe Bispecific Antibodies, by Indication USD Million (2022-2027)
  • Table 285. Rest of Europe Bispecific Antibodies, by Distribution Channel USD Million (2022-2027)
  • Table 286. MEA Bispecific Antibodies, by Country USD Million (2022-2027)
  • Table 287. MEA Bispecific Antibodies, by Type USD Million (2022-2027)
  • Table 288. MEA Bispecific Antibodies, by Application USD Million (2022-2027)
  • Table 289. MEA Bispecific Antibodies, by Drug USD Million (2022-2027)
  • Table 290. MEA Bispecific Antibodies, by Indication USD Million (2022-2027)
  • Table 291. MEA Bispecific Antibodies, by Distribution Channel USD Million (2022-2027)
  • Table 292. Middle East Bispecific Antibodies, by Type USD Million (2022-2027)
  • Table 293. Middle East Bispecific Antibodies, by Application USD Million (2022-2027)
  • Table 294. Middle East Bispecific Antibodies, by Drug USD Million (2022-2027)
  • Table 295. Middle East Bispecific Antibodies, by Indication USD Million (2022-2027)
  • Table 296. Middle East Bispecific Antibodies, by Distribution Channel USD Million (2022-2027)
  • Table 297. Africa Bispecific Antibodies, by Type USD Million (2022-2027)
  • Table 298. Africa Bispecific Antibodies, by Application USD Million (2022-2027)
  • Table 299. Africa Bispecific Antibodies, by Drug USD Million (2022-2027)
  • Table 300. Africa Bispecific Antibodies, by Indication USD Million (2022-2027)
  • Table 301. Africa Bispecific Antibodies, by Distribution Channel USD Million (2022-2027)
  • Table 302. North America Bispecific Antibodies, by Country USD Million (2022-2027)
  • Table 303. North America Bispecific Antibodies, by Type USD Million (2022-2027)
  • Table 304. North America Bispecific Antibodies, by Application USD Million (2022-2027)
  • Table 305. North America Bispecific Antibodies, by Drug USD Million (2022-2027)
  • Table 306. North America Bispecific Antibodies, by Indication USD Million (2022-2027)
  • Table 307. North America Bispecific Antibodies, by Distribution Channel USD Million (2022-2027)
  • Table 308. United States Bispecific Antibodies, by Type USD Million (2022-2027)
  • Table 309. United States Bispecific Antibodies, by Application USD Million (2022-2027)
  • Table 310. United States Bispecific Antibodies, by Drug USD Million (2022-2027)
  • Table 311. United States Bispecific Antibodies, by Indication USD Million (2022-2027)
  • Table 312. United States Bispecific Antibodies, by Distribution Channel USD Million (2022-2027)
  • Table 313. Canada Bispecific Antibodies, by Type USD Million (2022-2027)
  • Table 314. Canada Bispecific Antibodies, by Application USD Million (2022-2027)
  • Table 315. Canada Bispecific Antibodies, by Drug USD Million (2022-2027)
  • Table 316. Canada Bispecific Antibodies, by Indication USD Million (2022-2027)
  • Table 317. Canada Bispecific Antibodies, by Distribution Channel USD Million (2022-2027)
  • Table 318. Mexico Bispecific Antibodies, by Type USD Million (2022-2027)
  • Table 319. Mexico Bispecific Antibodies, by Application USD Million (2022-2027)
  • Table 320. Mexico Bispecific Antibodies, by Drug USD Million (2022-2027)
  • Table 321. Mexico Bispecific Antibodies, by Indication USD Million (2022-2027)
  • Table 322. Mexico Bispecific Antibodies, by Distribution Channel USD Million (2022-2027)
  • Table 323. Bispecific Antibodies: by Type(USD/Units)
  • Table 324. Research Programs/Design for This Report
  • Table 325. Key Data Information from Secondary Sources
  • Table 326. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Bispecific Antibodies: by Type USD Million (2016-2021)
  • Figure 5. Global Bispecific Antibodies: by Application USD Million (2016-2021)
  • Figure 6. Global Bispecific Antibodies: by Drug USD Million (2016-2021)
  • Figure 7. Global Bispecific Antibodies: by Indication USD Million (2016-2021)
  • Figure 8. Global Bispecific Antibodies: by Distribution Channel USD Million (2016-2021)
  • Figure 9. South America Bispecific Antibodies Share (%), by Country
  • Figure 10. Asia Pacific Bispecific Antibodies Share (%), by Country
  • Figure 11. Europe Bispecific Antibodies Share (%), by Country
  • Figure 12. MEA Bispecific Antibodies Share (%), by Country
  • Figure 13. North America Bispecific Antibodies Share (%), by Country
  • Figure 14. Global Bispecific Antibodies: by Type USD/Units (2016-2021)
  • Figure 15. Global Bispecific Antibodies share by Players 2021 (%)
  • Figure 16. Global Bispecific Antibodies share by Players (Top 3) 2021(%)
  • Figure 17. Global Bispecific Antibodies share by Players (Top 5) 2021(%)
  • Figure 18. BCG Matrix for key Companies
  • Figure 19. Amgen, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 20. Amgen, Inc. (United States) Revenue: by Geography 2021
  • Figure 21. Bayer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 22. Bayer AG (Germany) Revenue: by Geography 2021
  • Figure 23. Dow Pharmaceutical Solutions Revenue, Net Income and Gross profit
  • Figure 24. Dow Pharmaceutical Solutions Revenue: by Geography 2021
  • Figure 25. ImmunGene, Inc. Revenue, Net Income and Gross profit
  • Figure 26. ImmunGene, Inc. Revenue: by Geography 2021
  • Figure 27. Immunocore Limited (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 28. Immunocore Limited (United Kingdom) Revenue: by Geography 2021
  • Figure 29. Merck & Co., Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 30. Merck & Co., Inc. (United States) Revenue: by Geography 2021
  • Figure 31. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 32. Novartis AG (Switzerland) Revenue: by Geography 2021
  • Figure 33. Pfizer, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 34. Pfizer, Inc. (United States) Revenue: by Geography 2021
  • Figure 35. F. Hoffmann-La Roche AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 36. F. Hoffmann-La Roche AG (Switzerland) Revenue: by Geography 2021
  • Figure 37. Global Bispecific Antibodies: by Type USD Million (2022-2027)
  • Figure 38. Global Bispecific Antibodies: by Application USD Million (2022-2027)
  • Figure 39. Global Bispecific Antibodies: by Drug USD Million (2022-2027)
  • Figure 40. Global Bispecific Antibodies: by Indication USD Million (2022-2027)
  • Figure 41. Global Bispecific Antibodies: by Distribution Channel USD Million (2022-2027)
  • Figure 42. South America Bispecific Antibodies Share (%), by Country
  • Figure 43. Asia Pacific Bispecific Antibodies Share (%), by Country
  • Figure 44. Europe Bispecific Antibodies Share (%), by Country
  • Figure 45. MEA Bispecific Antibodies Share (%), by Country
  • Figure 46. North America Bispecific Antibodies Share (%), by Country
  • Figure 47. Global Bispecific Antibodies: by Type USD/Units (2022-2027)
List of companies from research coverage that are profiled in the study
  • Amgen, Inc. (United States)
  • Bayer AG (Germany)
  • Dow Pharmaceutical Solutions
  • ImmunGene, Inc.
  • Immunocore Limited (United Kingdom)
  • Merck & Co., Inc. (United States)
  • Novartis AG (Switzerland)
  • Pfizer, Inc. (United States)
  • F. Hoffmann-La Roche AG (Switzerland)
Select User Access Type

Key Highlights of Report


Jul 2022 165 Pages 92 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Bispecific Antibodies Market Quantitative research analysis
Global Bispecific Antibodies Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Amgen, Inc. (United States), Bayer AG (Germany), Dow Pharmaceutical Solutions, ImmunGene, Inc., Immunocore Limited (United Kingdom), Merck & Co., Inc. (United States), Novartis AG (Switzerland), Pfizer, Inc. (United States) and F. Hoffmann-La Roche AG (Switzerland) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Increase in Advanced Research Activities" is seen as one of major influencing trends for Bispecific Antibodies Market during projected period 2021-2027.
The Bispecific Antibodies market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Bispecific Antibodies Market Report?

Have a Query? Click Here

Other Related Reports

Automated Gram Stainer Comprehensive Study by Application (In-house Research, Commercial Research, Clinical Diagnosis), Slide Capacity (Upto 12 Slide, 13 - 30 slides, 31 -50 slides, Above 50 slides),...
$ 3650
Cellular Therapy in Oncology Comprehensive Study by Type (Consumables, Equipment (Cell Processing Equipment, Single-use Equipment), Systems & Software), Technology (Bioreactor, Cell Immortalization T...
$ 3750
Tissue Engineering and Organ Regeneration Comprehensive Study by Type (Tissue-engineered Products, Cell Therapies (Autologous Therapies, Allogenic Therapies), Gene Therapies, Progenitor & Stem Cell T...
$ 3650
Somatic Genetic Testing Comprehensive Study by Type (Product (Kits and Assays, Instruments, and Software), Services), Application (Solid Tumors (Breast Cancer, Prostate Cancer, Colorectal Cancer, Lun...
$ 3750
Minichromosomal Technology Comprehensive Study by Type (Reagents & Consumables, Software & Systems, Services), Application (Cell Line Engineering, Genetic Engineering, Diagnostic Applications, Drug D...
$ 3650
Home Insemination Products Comprehensive Study by Type (Insemination Kits, Home Conception Devices, Accessories), Distribution Channel (Online, Offline), End User (Hospitals &Clinics, Fertility Centr...
$ 3500